Liver Learnings: more news and updates

Fatty liver, hepatic regeneration, PREMIUM CONTENT subscriber access

Some of the liver disease societies voted last month to change the name of nonalcoholic steatohepatitis/NASH to the even longer name of metabolic dysfunction-associated steatohepatitis/MASH. Not sure what benefit that brings to the picture [I think they are trying to be ‘woke’]. FDA chooses to use the new umbrella term, ‘steatotic liver disease’.

For more info, I point you to my earlier post on NASH and the promising treatments described there:

As a followup, Madrigal completed their phase III trials of their thyroid hormone analogue, Resmetirom. Their rolling NDA submission to the FDA is under review for the NASH indication.

Of course, big Pharma’s research push for their marketed products - the GLP-1 analogues. I did help Novo Nordisk develop oral formulations for their candidate drugs, … way back in 2007. And so … I do know them very well.